BREAKING NEWS

EU antitrust regulators investigating Teva over its Copaxone drug

EU antitrust regulators are investigating Israeli drugmaker Teva over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, the European Commission said on Friday.
The EU competition enforcer raided Teva in October last year and in January this year as part of its investigation.
Teva can face fines up to 10% of its global turnover if found guilty of breaching EU antitrust rules. 
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use

Read all Tweets >